MedTrace Logo

Kidney Allograft Dysfunction Without Reversible Causes

NCT01492894 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2016-12-09

No results posted yet for this study

Summary

The purpose of this study is to learn the best way to prolong kidney life in patients exposed to calcineurin inhibitors, who already have evidence of damage possibly caused by the calcineurin inhibitor on kidney biopsy.

Conditions

  • Kidney Graft Dysfunction

Interventions

DRUG

Cyclosporins/Tacrolimus

Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels

DRUG

Sirolimus

Change from current calcineurin inhibitor to Sirolumus

Sponsors & Collaborators

Principal Investigators

  • Aleksandra Kukula, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492894 on ClinicalTrials.gov